Future efforts should therefore be focused on developing non-toxic and highly specific small molecule inhibitors of the LDH-A subunit, in order to block glycolysis, particularly in those tumours which have absent or decreased expression of the LDH-B subunit, thus, 'cutting-off' a major pathway used by breast and other cancer cells for their energy production. The gene discussed is LDHB; the disease is neoplasm.